文献速递乳腺癌

设计可接受新治疗臂的临床试验:转移性乳腺癌中的示例

Designing Clinical Trials That Accept New Arms: An Example in Metastatic Breast Cancer.
PubMed 文献 · J Clin Oncol · 2017-05-22

该研究提出一种滚动臂平台设计,允许在试验进行中动态添加和移除治疗臂,并以激素受体阳性、人表皮生长因子受体2阴性晚期乳腺癌中多种CDK4/6抑制剂联合来曲唑的独立两臂试验为场景进行模拟。结果显示,含2至5个实验治疗的滚动臂设计可使总样本量需求较标准两臂研究降低至多30%,对照组患者数减少至多60%,并在现实情景下提前至多15个月发现有效实验治疗。作者认为该设计适用于多种疾病,且在现实情景下效率显著高于标准两臂随机试验。

要点

  • 滚动臂平台设计允许试验进行中动态添加和移除治疗臂,共享共同对照组。
  • 模拟显示含2至5个实验治疗的滚动臂设计较标准两臂研究降低总样本量需求至多30%。
  • 该设计较五个独立两臂试验减少对照组患者至多60%,并提前至多15个月发现有效治疗。

核心结论

  • 滚动臂平台设计适用于多种疾病,且在现实情景下效率显著高于标准两臂随机试验。

研究设计与样本

  • 研究定义滚动臂设计以最小化平台试验随机分配和数据分析的复杂性,并评估其在激素受体阳性、人表皮生长因子受体2阴性晚期乳腺癌中的潜在优势。
  • 研究采用模拟研究量化若多种CDK4/6抑制剂联合来曲唑在滚动臂试验中测试时,样本量、接受标准治疗的患者数及平均治疗发现时间的减少。

主要发现

  • 含2至5个实验治疗的滚动臂平台设计较标准两臂研究降低总样本量需求至多30%。
  • 滚动臂平台设计较测试不同治疗的五个独立试验减少对照组患者至多60%。
  • 在现实情景下,滚动臂平台设计较独立两臂试验提前至多15个月发现有效实验治疗。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Purpose The majority of randomized oncology trials are two-arm studies that test the efficacy of new therapies against a standard of care, thereby assigning a large proportion of patients to nonexperimental therapies. In contrast, multiarm studies efficiently share a common control arm while evaluating multiple experimental therapies. A major bottleneck for traditional multiarm trials is the requirement that all therapies-often drugs from different companies-have to be available at the same time when the trial starts. We evaluate the potential gains of a platform design-the rolling-arms design-that adds and removes arms on a rolling basis. Methods We define the rolling-arms design with the goal of minimizing the complexity of random assignment and data analyses of a platform trial. We then evaluate its potential advantages in hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer. Multiple pharmaceutical companies currently test CDK4/6 inhibitors in combination with letrozole in independent two-arm trials. We conducted a simulation study to quantify the reduction in sample size, number of patients treated with the standard of care, and the average time to treatment discovery if these therapies had been tested in a rolling-arms trial. Results A rolling-arms platform design with two to five experimental treatments can reduce the overall sample size requirement by up to 30% compared with standard two-arm studies. It assigns up to 60% fewer patients to the control arm compared with five independent trials that test distinct treatments. Moreover, under realistic scenarios, effective experimental treatments are discovered up to 15 months earlier compared with separate two-arm trials. Conclusion The rolling-arms platform design is applicable to a broad variety of diseases, and under realistic scenarios, it is substantially more efficient than standard two-arm randomized trials.

来源:J Clin Oncol,查看原文。版权归原作者所有。

引用

  1. Ventz S, Alexander BM, Parmigiani G, et al. Designing Clinical Trials That Accept New Arms: An Example in Metastatic Breast Cancer. J Clin Oncol. 2017. PMID: 28530853. doi:10.1200/JCO.2016.70.1169

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。